Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Change in Account Payables (2020 - 2025)

Vivos Therapeutics (VVOS) has disclosed Change in Account Payables for 6 consecutive years, with $340000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Account Payables rose 135.68% to $340000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $970000.0, a 313.66% increase, with the full-year FY2024 number at -$1.0 million, down 242.78% from a year prior.
  • Change in Account Payables was $340000.0 for Q3 2025 at Vivos Therapeutics, down from $499000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $902000.0 in Q3 2021 to a low of -$1.4 million in Q1 2021.
  • A 5-year average of $66526.3 and a median of $204000.0 in 2023 define the central range for Change in Account Payables.
  • Biggest YoY gain for Change in Account Payables was 321.43% in 2024; the steepest drop was 567.16% in 2024.
  • Vivos Therapeutics' Change in Account Payables stood at $220000.0 in 2021, then surged by 248.64% to $767000.0 in 2022, then fell by 19.69% to $616000.0 in 2023, then crashed by 96.43% to $22000.0 in 2024, then surged by 1445.45% to $340000.0 in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Change in Account Payables are $340000.0 (Q3 2025), $499000.0 (Q2 2025), and $109000.0 (Q1 2025).